Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.

Saved in:
Bibliographic Details
Title: Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.
Authors: Vigneron SF; Department of Pharmaceutical Chemistry, University of California, San Francisco., Ohno S; Department of Chemistry, Yale University., Braz J; Department of Anatomy, University of California, San Francisco., Kim JY; Department of Pharmaceutical Chemistry, University of California, San Francisco., Kweon OS; Department of Chemistry, Yale University., Webb C; Department of Pharmaceutical Chemistry, University of California, San Francisco., Billesbølle C; Department of Pharmaceutical Chemistry, University of California, San Francisco., Bhardwaj K; Department of Anatomy, University of California, San Francisco., Irwin J; Department of Pharmaceutical Chemistry, University of California, San Francisco., Manglik A; Department of Pharmaceutical Chemistry, University of California, San Francisco., Basbaum AI; Department of Anatomy, University of California, San Francisco., Ellman JA; Department of Chemistry, Yale University., Shoichet BK; Department of Pharmaceutical Chemistry, University of California, San Francisco.
Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 Jan 14. Date of Electronic Publication: 2025 Jan 14.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2692-8205
DOI:10.1101/2025.01.09.632033